AN Shoutko*

Trasplantology and Stem Cells Department (TSC dept), A.M Granov’s Russian Research Center for Radiology and Surgical Technologies, (A.M Granov’s RRCRST), Russia

*Corresponding Author: AN Shoutko, Trasplantology and Stem Cells Department (TSC dept), A.M Granov’s Russian Research Center for Radiology and Surgical Technologies, (A.M Granov’s RRCRST), Russia.

Received: June 07, 2022; Published: June 21, 2022

Abstract

Introduction: Three general types of survival by age characterize the effectiveness of conventional cancer treatment in a population of developed country. To explain big difference between received results, the microenvironment of normal tissues investigated and compared with clinical data.

Material and Method: Open database for cancer survival by age in UK and open database for human proteins in normal human tissues used for extraction of original information for 16 cancers () and 18 proteins in normal tissues, which are host/primary for corresponding malignancy. All original data for protein levels transformed by normalization to both level in bone marrow. The transformed data were analyzed and compared with three general types survival by age, using statistical instruments of Excel.

Results: Three cohorts of sixteen cancers of UK population’s data differ around 7 times according to exponential rate of survival’s decline by age. The average result of therapy in cohorts is better, the higher the average level of markers for hematopoietic (CD34) and vasculogenic (CD31) cells in normal tissues corresponded to cancer’s cohorts. The level of immune markers for T-, B-cells, and neutrophils in normal tissues are lower, than stem cells, young lymphoid descendants, and endothelial ones. The result of therapy in cohorts is the better, the lover level of immune markers in normal tissues, corresponded to cohorts i.e.the more shift to the "stemness" in the differentiation's range. The number of markers for hematopoietic stem cells and their descendants in normal tissues varies in the opposite way.

Discussion: Despite common domination of hematopoietic stem cells markers in normal tissues, their number may vary by physiology of inter-organs flows of the fluids. The higher morphogenic resource of CD34 and CD31 in normal tissue can extend the local tumor growth, delay a coming hypoxia, metastases, and death.

Conclusion: The proteins microenvironment of normal human tissues, as a host of unpredictable malignancy, does not correspond completely to the usual markers in terms of circulating blood cells. The domination of “CD34- stemness” and “CD31-vasculogenity” provide a local longevity of tumor and thus delay the shift of its logarithmic growth into quasi-linear, the offensive of hypoxia, followed metastases and death.

Keywords: Survival; Age Population; Cancers; Normal Host-Tissues; Protein Tissue Markers; Hematopoietic Stem Cells; Circulating Cells

References

1. Shoutko AN., et al. “The Impact of Middle Age on the Viability of Patients with Nonmalignant and Malignant Diseases”. Cancer Research Journal6 (2014): 114-120.
2. Seim I., et al. “Gene expression signatures of human cell and tissue longevity”. npj Aging and Mechanisms of Disease 16014 (2016): 1-8.
3. The Human Protein Atlas. Version: 21. Atlas updated: 2021-11-18.
4. Office for National Statistics. Statistical Bulletin: Cancer survival in England: Patients diagnosed 2007-2011 and followed up to 2012. Newport: ONS (2013).
5. Quaresma M., et al. “40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales”. Lancet (2015).
6. Stewart DJ., et al. “Exponential decay nonlinear regression analysis of patient survival curves: Preliminary assessment in non-small cell lung cancer”. Lung Cancer 71 (2011): 217-223.
7. Azouna NB., et al. “Immunophenotyping of Hematopoietic Progenitor Cells: Comparison between Cord Blood and Adult Mobilized Blood Grafts”. World Journal of Stem Cells 3 (2011): 104-112.
8. Song M., et al. “Neutrophil‑to‑lymphocyte ratio and mortality in the United States general population”. Nature Research 464 (2021): 1-9.
9. Gore SD., et al. “Normal Human Bone Marrow Precursors That Express Terminal Deoxynucleotidyl Transferase Include T-cell Precursors and Possible Lymphoid Stem Cells”. Blood 8 (1991): 1681-1690.
10. Liu P., et al. “Abnormal CD25 expression on hematopoietic cells in myelodysplastic Syndromes”. Leukemia Research 67 (2018): 12-16.
11. Ginaldi L., et al. “Differential expression of T cell antigens in normal peripheral blood lymphocytes: a quantitative analysis by flow cytometry”. Clinical Pathology 49 (1996): 539-544.
12. Agras P. I., et al. “Hyperleptinemia and its relation with peripheral C34+CD7+ stem cells in renal transplant recipients”. Transplant Immunology 15 (2006): 241-245.
13. Wei S., et al. “Dysfunctional immunoregulation in human liver allograft rejection associated with compromised galectin-1/CD7 pathway function”. Cell Death and Disease293 (2018): 1-13.
14. Stepanova K and Sinkora M. “Porcine γẟ T Lymphocytes Can Be Categorized into Two Functionally and Developmentally Distinct Subsets according to Expression of CD2 and Level of TCR”. Journal of Immunology 190 (2013): 2111-2120.
15. Zhao Y., et al. “Gamma‑delta (γδ) T cells: friend or foe in cancer development? ”. Journal of Translational Medicine 3 (2018): 1-13.
16. Blank C., et al. “Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: Implications for tumor immunotherapy”. Cancer Immunology and Immunotherapy 54 (2005): 307-314.
17. Abdellatif H and Shiha G. “PD-L1 “Expression on Circulating CD34＋ Hematopoietic Stem Cells Closely Correlated with T-cell Apoptosis in Chronic Hepatitis C Infected Patients”. International Journal of Stem Cells 1 (2018): 78-86.
18. Billaud M., et al. “Classification and Functional Characterization of Vasa Vasorum-Associated Perivascular Progenitor Cells in Human Aorta”. Stem Cell Reports1 (2017): 292-303.
19. Wang Ch., et al. “Efficient Differentiation of Bone Marrow Mesenchymal Stem Cells into Endothelial Cells in Vitro”. European Journal of Vascular and Endovascular Surgery 257e265 (2018): 257-265.
20. Kim SW., et al. “Human Peripheral Blood-Derived CD31+ Have Robust Angiogenic and Vasculogenic Properties and Are Effective for Treating Ischemic Vascular Disease”. Journal of the American College of Cardiology 7 (2010): 593-607.
21. Monaco M CG., et al. “Identification of circulating CD31+CD45+cell populations with the potential to differentiate into erythroid cells”. Stem Cell Research and Therapy 236 (2021): 1-5.
22. Font-Clos F., et al. “Blood Flow Contributions to Cancer Metastasis”. iScience 5 (2020): 101073.
23. Ochtrop M.L.G., et al. “T and B lymphocyte abnormalities in bone marrow biopsies of common variable immunodeficiency”. BLOOD2 (2011): 309-318.
24. Sidney L. E., et al. “Evidence for CD34 as a Common Marker for Diverse Progenitors”. Stem Cells6 (2014): 1380-1389.
25. Kilpatrick R. D., et al. “Homeostasis of the Naive CD4+ T Cell Compartment during Aging”. Journal of Immunology 180 (2008): 1499-1507.
26. Larbi A and Fulop T. “From “Truly Naive” to “Exhausted Senescent” T Cells: When Markers Predict Functionality”. Cytometry Part A 85A (2014): 25-35.
27. Ginaldi L., et al. “Differential expression of T cell antigens in normal peripheral blood lymphocytes: a quantitative analysis by flow cytometry”. Journal of Clinical Pathology7 (1996): 539-544.
28. Keir ME., et al. “Programmed Death-1 (PD-1): PD-Ligand”. Journal of Immunology11 (2005): 7372-7379.
29. Shoutko AN., et al. “Non-Invasive Vibration-Stress of the Cirrhotic Liver of Patients Waiting for Transplantation Induces of Circulating CD133+ Stem Lymphocytes Committed Phenotypically toward the Liver”. Open Journal of Biophysics03 (2019): 155-168.
30. Hénon P and Lahlil R. “CD34+ Stem Cells and Regenerative medicine”. 21-34. In book: Stem Cells, Latest Advances. p256. Editor K.H. Haider. 2021. Springer Nature, Cham, Switzerland (eBook) (2021).
31. Moskorz W., et al. “Myelodysplastic syndrome patients display alterations in their immune status reflected by increased PD-L1-expressing stem cells and highly dynamic exhausted T-cell frequencies”. British Journal of Haematology 5 (2021): 941-945.
32. Bakhashab S., et al. “Weaver Metformin improves the angiogenic potential of human CD34+ cells co‑incident with downregulating CXCL10 and TIMP1 gene expression and increasing VEGFA under hyperglycemia and hypoxia within a therapeutic window for myocardial infarction”. Cardiovascular Diabetology 27 (2016): 1-12.
33. Lugano R., et al. “Tumor angiogenesis: causes, consequences, challenges and opportunities”. Cellular and Molecular Life Sciences 77 (2020): 1745-1770.
34. West J and PK Newton “Cellular interactions constrain tumor growth”. PNAS6 (2019): 1918-1923.
35. Lyden D., et al. “Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth”. Nature Medicine 7 (2001): 1194-1201.
36. Muz B., et al. “The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy”. Hypoxia 11 (2015): 83-92.

Citation

Citation: AN Shoutko. “Tissues Protein Microenvironment and Survival by Age at Cancers".Acta Scientific Cancer Biology 6.7 (2022): .

Copyright

Copyright: © 2022 AN Shoutko. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.